US lawmakers are moving toward a tighter policy posture on China biotech investment and in-licensing restrictions, with a House committee slated to vote on proposals that add BINSA research restrictions and domestic biomanufacturing support to the National Defense Authorization Act. Separately, the question of “don’t restrict Chinese biotech” has reignited debate over whether data from China should be treated differently in US review and whether restrictive licensing rules block patient access to faster, cheaper therapies. For biotech dealmakers and investors, the immediate impact is that licensing structures, trial evidence expectations, and portfolio strategy may shift as political risk becomes a primary pricing variable.